Plain-English translation of NCT07282210 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Sickle Cell Disease research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing whether a medication called can help people with sickle cell disease by reducing the breakdown of red blood cells in their body. Researchers want to see if this medication, taken as a daily pill alongside your current hydroxyurea treatment, can improve your health and quality of life. About 105 people will participate, and half will receive the new medication while half receive a placebo (dummy pill) to compare results fairly.
Many people with sickle cell disease experience complications from the rapid breakdown of red blood cells, which can worsen their condition even when they're already taking standard treatments like hydroxyurea. This trial is exploring whether this medication might offer additional protection by slowing down that cell breakdown process.
You likely qualify if…
You likely don't qualify if…
You would take the study medication (or placebo) by mouth daily for up to 24 weeks while continuing your regular hydroxyurea treatment. The first 4 days involve taking two pills, then you switch to one pill daily for the remainder of the study. You'll have regular visits with the research team to check your health, have blood tests done, and report how you're feeling—allowing doctors to track whether the medication is helping reduce blood cell breakdown and improve your overall wellbeing.
AI-generated summary from trial data · Aug 22, 2026 · Not medical advice
Canada